Cargando…

Advancing Cancer Research: Current Knowledge on Cutaneous Neoplasia

Skin cancers require a multidisciplinary approach. The updated guidelines introduce new insights into the management of these diseases. Melanoma (MM), the third most common skin cancer, a malignant melanocytic tumor, which is classified into four major histological subtypes, continues to have the po...

Descripción completa

Detalles Bibliográficos
Autores principales: Stătescu, Laura, Trandafir, Laura Mihaela, Țarcă, Elena, Moscalu, Mihaela, Leon Constantin, Maria Magdalena, Butnariu, Lăcrămioara Ionela, Trandafirescu, Mioara Florentina, Tîrnovanu, Mihaela Camelia, Heredea, Rodica, Pătrașcu, Andrei Valentin, Botezat, Doru, Cojocaru, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342314/
https://www.ncbi.nlm.nih.gov/pubmed/37446352
http://dx.doi.org/10.3390/ijms241311176
_version_ 1785072469477949440
author Stătescu, Laura
Trandafir, Laura Mihaela
Țarcă, Elena
Moscalu, Mihaela
Leon Constantin, Maria Magdalena
Butnariu, Lăcrămioara Ionela
Trandafirescu, Mioara Florentina
Tîrnovanu, Mihaela Camelia
Heredea, Rodica
Pătrașcu, Andrei Valentin
Botezat, Doru
Cojocaru, Elena
author_facet Stătescu, Laura
Trandafir, Laura Mihaela
Țarcă, Elena
Moscalu, Mihaela
Leon Constantin, Maria Magdalena
Butnariu, Lăcrămioara Ionela
Trandafirescu, Mioara Florentina
Tîrnovanu, Mihaela Camelia
Heredea, Rodica
Pătrașcu, Andrei Valentin
Botezat, Doru
Cojocaru, Elena
author_sort Stătescu, Laura
collection PubMed
description Skin cancers require a multidisciplinary approach. The updated guidelines introduce new insights into the management of these diseases. Melanoma (MM), the third most common skin cancer, a malignant melanocytic tumor, which is classified into four major histological subtypes, continues to have the potential to be a lethal disease. The mortality–incidence ratio is higher in Eastern European countries compared to Western European countries, which shows the need for better prevention and early detection in Eastern European countries. Basal cell carcinoma (BCC) and squamous cell carcinoma (cSCC) remain the top two skin cancers, and their incidence continues to grow. The gold standard in establishing the diagnosis and establishing the histopathological subtype in BCC and SCC is a skin biopsy. Sebaceous carcinoma (SeC) is an uncommon and potentially aggressive cutaneous malignancy showing sebaceous differentiation. It accounts for 0.7% of skin cancers and 3–6.7% of cancer-related deaths. Due to the rapid extension to the regional lymph nodes, SeC requires early treatment. The main treatment for sebaceous carcinoma is surgical treatment, including Mohs micrographic surgery, which has the advantage of complete margin evaluation and low recurrence rates. Primary cutaneous lymphomas (PCLs) are a heterogeneous group of lymphoproliferative diseases, with no evidence of extracutaneous determination at the moment of the diagnosis. PCLs have usually a very different evolution, prognosis, and treatment compared to the lymphomas that may secondarily involve the skin. The aim of our review is to summarize the important changes in the approach to treating melanoma, non-melanoma skin, cutaneous T and B cell lymphomas, and other types of skin cancers. For all skin cancers, optimal patient management requires a multidisciplinary approach including dermatology, medical oncology, and radiation oncology.
format Online
Article
Text
id pubmed-10342314
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103423142023-07-14 Advancing Cancer Research: Current Knowledge on Cutaneous Neoplasia Stătescu, Laura Trandafir, Laura Mihaela Țarcă, Elena Moscalu, Mihaela Leon Constantin, Maria Magdalena Butnariu, Lăcrămioara Ionela Trandafirescu, Mioara Florentina Tîrnovanu, Mihaela Camelia Heredea, Rodica Pătrașcu, Andrei Valentin Botezat, Doru Cojocaru, Elena Int J Mol Sci Review Skin cancers require a multidisciplinary approach. The updated guidelines introduce new insights into the management of these diseases. Melanoma (MM), the third most common skin cancer, a malignant melanocytic tumor, which is classified into four major histological subtypes, continues to have the potential to be a lethal disease. The mortality–incidence ratio is higher in Eastern European countries compared to Western European countries, which shows the need for better prevention and early detection in Eastern European countries. Basal cell carcinoma (BCC) and squamous cell carcinoma (cSCC) remain the top two skin cancers, and their incidence continues to grow. The gold standard in establishing the diagnosis and establishing the histopathological subtype in BCC and SCC is a skin biopsy. Sebaceous carcinoma (SeC) is an uncommon and potentially aggressive cutaneous malignancy showing sebaceous differentiation. It accounts for 0.7% of skin cancers and 3–6.7% of cancer-related deaths. Due to the rapid extension to the regional lymph nodes, SeC requires early treatment. The main treatment for sebaceous carcinoma is surgical treatment, including Mohs micrographic surgery, which has the advantage of complete margin evaluation and low recurrence rates. Primary cutaneous lymphomas (PCLs) are a heterogeneous group of lymphoproliferative diseases, with no evidence of extracutaneous determination at the moment of the diagnosis. PCLs have usually a very different evolution, prognosis, and treatment compared to the lymphomas that may secondarily involve the skin. The aim of our review is to summarize the important changes in the approach to treating melanoma, non-melanoma skin, cutaneous T and B cell lymphomas, and other types of skin cancers. For all skin cancers, optimal patient management requires a multidisciplinary approach including dermatology, medical oncology, and radiation oncology. MDPI 2023-07-06 /pmc/articles/PMC10342314/ /pubmed/37446352 http://dx.doi.org/10.3390/ijms241311176 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Stătescu, Laura
Trandafir, Laura Mihaela
Țarcă, Elena
Moscalu, Mihaela
Leon Constantin, Maria Magdalena
Butnariu, Lăcrămioara Ionela
Trandafirescu, Mioara Florentina
Tîrnovanu, Mihaela Camelia
Heredea, Rodica
Pătrașcu, Andrei Valentin
Botezat, Doru
Cojocaru, Elena
Advancing Cancer Research: Current Knowledge on Cutaneous Neoplasia
title Advancing Cancer Research: Current Knowledge on Cutaneous Neoplasia
title_full Advancing Cancer Research: Current Knowledge on Cutaneous Neoplasia
title_fullStr Advancing Cancer Research: Current Knowledge on Cutaneous Neoplasia
title_full_unstemmed Advancing Cancer Research: Current Knowledge on Cutaneous Neoplasia
title_short Advancing Cancer Research: Current Knowledge on Cutaneous Neoplasia
title_sort advancing cancer research: current knowledge on cutaneous neoplasia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342314/
https://www.ncbi.nlm.nih.gov/pubmed/37446352
http://dx.doi.org/10.3390/ijms241311176
work_keys_str_mv AT statesculaura advancingcancerresearchcurrentknowledgeoncutaneousneoplasia
AT trandafirlauramihaela advancingcancerresearchcurrentknowledgeoncutaneousneoplasia
AT tarcaelena advancingcancerresearchcurrentknowledgeoncutaneousneoplasia
AT moscalumihaela advancingcancerresearchcurrentknowledgeoncutaneousneoplasia
AT leonconstantinmariamagdalena advancingcancerresearchcurrentknowledgeoncutaneousneoplasia
AT butnariulacramioaraionela advancingcancerresearchcurrentknowledgeoncutaneousneoplasia
AT trandafirescumioaraflorentina advancingcancerresearchcurrentknowledgeoncutaneousneoplasia
AT tirnovanumihaelacamelia advancingcancerresearchcurrentknowledgeoncutaneousneoplasia
AT heredearodica advancingcancerresearchcurrentknowledgeoncutaneousneoplasia
AT patrascuandreivalentin advancingcancerresearchcurrentknowledgeoncutaneousneoplasia
AT botezatdoru advancingcancerresearchcurrentknowledgeoncutaneousneoplasia
AT cojocaruelena advancingcancerresearchcurrentknowledgeoncutaneousneoplasia